BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 5, 2026
See today's BioWorld
Home
» GenVec Plans Merger With Diacrin Through $40M Stock Transaction
To read the full story,
subscribe
or
sign in
.
GenVec Plans Merger With Diacrin Through $40M Stock Transaction
April 16, 2003
By
Brady Huggett
Not to compare the biotechnology industry - with its blockbuster drugs and groundbreaking science - with a flea market, but there are good deals in this depressed environment if you look around. (BioWorld Today)
BioWorld